Clinical Trial Search

Primary: Time From Start of Administration of Investigational Medicinal Product (IMP, Sugammadex or Placebo) to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9…

Primary: Change in Mean Clinical Attachment Level. — 0.11; 0.10; 0.21; 0.08 mm — p=>0.05

Primary: Titers of Serum Haemagglutination-inhibition (HI) Antibodies Against Each of the 3 Influenza Strains Assessed. — 31.9; 36.1; 26.1; 475.4 HIU

Primary: Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Individual Item Scores for the Overall Study Population — 5.0; 5.4; 4.8; 2.4 units on a scale

Primary: Efficacy Assessment After a Total of at Least 50 EDs Per Subject at the End of the Study at 6 Months — 0.188 Bleeds per month

Primary: The Incidence of Predefined Cardiovascular Treatment-Emergent Adverse Events (TEAEs) in Epilepsy Patients With Partial-onset Seizures While on Vimpat or Any Other add-on…

Primary: Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index — 1.91; 0.84 units on a scale — p=0.001

Primary: Clinical Utility of Biweekly β-D-glucan (BDG) Testing in At-risk Intensive Care Unit (ICU) Patients. — 3; 3; 19; 9 participants

Primary: Cure Rate — 16.3; 28.3; 18.8 percentage of participants

Primary: Change From Period Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1) — 0.27; -0.12; 0.37 liters — p=< 0.0001

Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 (FDA Snapshot Analysis) — 100 percentage of participants

Primary: Number of Post-ERCP Pancreatitis Cases in Participants Who Are Administered Aprepitant and Placebo Prior to ERCP and One Day After ERCP:Assess the Total Number of…

Primary: Documented Infection Rate — 58; 41 Infections

Primary: Mean Percent Change From Baseline in Whole-body Insulin Sensitivity — 87.4; 63.1 percentage of change from baseline

Primary: Figure 8 Walking Speed Before and After Intervention. — .337; .312; .261; .432 meters/second